In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Adams Street and Latterell lead Naurex’s $18mm Series A financing

11 Jun 2021

Executive Summary

Adams Street Partners and Latterell Venture Partners co-led neurology therapeutics developer Naurex Inc.’s $18mm Series A financing, which also included investments by Druid BioVentures, Genesys Capital, PathoCapital, H. Lundbeck AS, Takeda Ventures, and Shire PLC. A member of PathoCapital has become the company’s chairman, and executives from Adams and Latterell joined the board.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By